ACCF’s DISCLOSURE/CONFLICT OF INTEREST POLICY
It is the policy of the American College of Cardiology that audiences for any ACCF programs, products, policies, services and scientific publications (“activities”) must be informed, prior to their participation, of ACCF’s and individual ACCF contributors’ relevant relationships with commercial interests in any proprietary entity producing health care goods or services (with the exception of nonprofit or government organizations and non-health care related companies). Contributors will include directors, planners, reviewers, moderators, speakers, faculty and authors and editors of programs, products, services and publications. All such contributors must disclose relevant relationships to ACCF annually in accordance with the policies and procedures described in this statement. ACCF will identify and resolve all conflicts of interest prior to a contributor’s participation in the program, product, policy, service and/or scientific publication.
ACCF’s policy also incorporates adherence to the following guidance:
1. American Medical Association’s (AMA) Opinion 8.061,
“Gifts to Physicians from Industry” (adopted December
1990) and Opinion 9.011, “Ethical Issues on CME”
(adopted by the AMA in December 1993 and updated June 1996).
2. Accreditation Council for Continuing Medical Education’s
(ACCME) “Standards for Commercial Support.”
3. Accreditation Council for Graduate Medical Education’s
(ACGME) “Principles to Guide the Relationship Between
Graduate Medical Education and Industry.”
4. American Nurses Credentialing Center’s Commission
on Accreditation, “Unit Operations Criterion.”
The ACCF very much appreciates the time, talent, and many
contributions made by members of ACCEL’s Editorial Board.
Please note that while Editorial Board members suggest topics
for interviews, they do not have influence over the interviews
that are selected for publication each month.
ACCEL Editorial Board
Editor in Chief
C. Richard Conti, MD
Research Grants: Medtronic, Inc.; Advisory Board: Vasomedical,
Inc.
Editor in Chief Emeritus
Sylvan L. Weinberg, MD
This editor has nothing to disclose.
Associate Editors
Jonathan Abrams, MD
Consultant/Speaker: Merck & Co., Inc., Pfizer Inc, AstraZeneca,
KOS, Bristol-Myers Squibb Company.
Raphael Balcon, MD
This associate editor has nothing to disclose.
Kenneth Lee Baughman, MD
This associate editor has nothing to disclose.
George A. Beller, MD
Research Grants: Bristol-Myers Squibb Company; Consultant:
Vasomedical, Inc.; Advisory Board: Vasomedical, Inc.; Board
Member: Adenosine Therapeutics.
Peter C. Block, MD
Advisory Board: Ample Medical, Cordis Corporation, Corevalve;
Stockholder: Direct Flow, Evalve.
William E. Boden, MD
Consultant: KOS; Research Grants: KOS, Merck & Co., Inc.,
Pfizer Inc, DuPont; Speaker's Bureau: KOS, Merck & Co,
Inc., Pfizer Inc, DuPont, Sanofi/Bristol-Myers Squibb, Aventis.
Lawrence I. Bonchek, MD
This associate editor has nothing to disclose.
Robert O. Bonow, MD
Consultant: Bristol-Myers Squibb, King Pharmaceuticals.
Alfred A. Bove, MD
Stock Options, Consulting Fees: Insight Telehealth Systems.
Gunter Breithardt, MD
Research Grants: Medtronic, Inc, Guidant Corporation, Biotronik;
Consultant: Medtronic, Inc., Guidant Corporation, Biotronik,
Cordis Corporation, Genzyme, AstaZeneca.
A. John Camm, MD
Consulting fees: Consultant: Procter & Gamble, Abbott, Astrallis, Boehringer, Ingelheim, Sanofi-Aventis, Guidant, St. Jude Medical, GSK, Servier, Wyeth; Speaker's Bureau: Vitatron, Medtronic
James H. Chesebro, MD
Research Grants: Berlex Lab.
W. Randolph Chitwood, Jr., MD
Consultant: Intuitive Surgical.
Lawrence H. Cohn, MD
Consultant: Edwards Life Sciences, Medtronic, Inc., St. Jude
Medical.
Jamie Beth Conti, MD
Research Grants: Medtronic, Inc.; Advisory Board: Guidant
Corporation, Medtronic, Inc.
Anthony N. DeMaria, MD
Stock Options: Resmed, Biosite, Targe GW; Consultant: Resmed,
Targe GW, Vasomedical, Inc.. Research Grants: Resmed, Acoufiant;
Speaker: Acoufiant. Employment: Resmed; Ownership/Partnership:
Resmed; Officer/Trustee: Resmed, Biosite; Receipt of Royalties:
Resmed.
James S. Forrester, MD
Consultant: Edwards Labs; Speaker’s Bureau: Merck &
Co., Inc., Pfizer Inc., AstraZeneca.
S. Ben Freedman, MB, BS, PhD
Advisory Board: AstraZeneca; Research: Servier; Speaker: Roche.
Valentin Fuster, MD, PhD
Consultant: GlaxoSmithKline; Chairman of the Global Advisory
Board and of the Foundation for CV Research: GlaxoSmithKline;
Advisory Board: Vasogen, Kereos, Inc.
W. Bruce Fye, MD, MA
This associate editor has nothing to disclose.
Bernard J. Gersh, MB, ChB, DPhil
Consultant: Boston Scientific; Advisory Board: AstraZeneca,
Aventis.
Raymond J. Gibbons, MD
Research Grants: Wyeth Ayerst Laboratories, Radiant Medical,
Medtronic, Inc., Ther Ox, Targe GW, KAI Pharmaceuticals; Consultant:
King Pharmaceuticals, CV Therapeutics, Hawaii Biotech, Consumers
Union, Cardiovascular Clinical Studies.
Paul C. Gillette, MD
This associate editor has nothing to disclose.
Mervyn S. Gotsman, MD
This associate editor's disclosures were not received at the
time of production of the May 2005 issue.
Phillip J. Harris, MB, BS, PhD
This associate editor has nothing to disclose.
David L. Hayes, MD
Speaker’s Fees: Medtronic, Inc., Guidant Corporation,
St. Jude Medical, ELA Medical; Consultant: Guidant Corporation;
Stock Holder: Medtronic, Inc., Pfizer Inc., Merck & Co.,
Inc.
John W. Hirshfeld, Jr., MD
This associate editor has nothing to disclose.
David R. Holmes, Jr., MD
This associate editor has nothing to disclose.
Adolph M. Hutter, Jr., MD
Consultant: Lilly-ICOS.
Spencer B. King, III, MD
Consultant: Bristol Myers Squibb, Sanofi, Medtronic, Inc.;
Royalties: Novoste Corporation; Officer / Trustee: GMP Company;
Speaker’s Bureaus: Bristol-Myers Squibb, Sanofi.
Richard P. Lewis, MD
This associate editor has nothing to disclose.
Attilio Maseri, MD
This associate editor's disclosures were not received at the time of production of the May 2005 issue.
Ben D. McCallister, MD
This associate editor has nothing to disclose.
Joseph V. Messer, MD
This associate editor has nothing to disclose.
Eric L. Michelson, MD
Employee: AstraZeneca.
Peter G. Mills, BM, BCh
This associate editor has nothing to disclose.
Gerald V. Naccarelli, MD
Research Grants: Wyeth-Ayerst Laboratories, Procter &
Gamble, Guidant Corporation, Sanofi-Synthelab Pharmaceuticals,
Medtronic, Inc.; Consultant: Medtronic, Inc., Wyeth-Ayerst
Laboratories, Procter & Gamble, GlaxoSmithKline, Sanofi-Synthelab
Pharmaceuticals, Guidant Corporation, Pfizer, Inc, Reliant
Pharmaceuticals.
Steven E. Nissen, MD
Research Grants: Pfizer Inc, AstraZeneca, Novartis, Takede,
Sankyo, Guidant Corporation; Consultant: Pfizer Inc, AstraZeneca,
Novartis, Takede, Sankyo, Guidant Corporation.
Jacqueline A. Noonan, MD
This associate editor has nothing to disclose.
E. Magnus Ohman, MD
Research Grants: Berlex Laboratories, Inc., Sanofi, Bristol-Myers
Squibb, Shering-Plough, Aventis, Millenium.
William W. O’Neil, MD
Research Grants: JJIS, Medtronic, Inc., Boston Scientific,
Guidant Corporation, Pfizer Inc.; Consultant: JJIS, Medtronic,
Inc., Boston Scientific, Guidant Corporation.
Carl J. Pepine, MD
Research Grants; Abbott Laboratories, AstraZeneca, Aventis
Pharmaceuticals, Inc., Berlex Laboratories, CV Therapeutics,
King Pharmaceuticals, Inc., Monarch Pharmaceuticals, Pfizer
Inc., Wyeth-Ayerst Laboratories; Consultant: Abbott Laboratories,
CV Therapeutics.
Betram Pitt, MD
Stock Options and Officer/Trustee: Ivax; Consultant: Pfizer
Inc, Novartis, Berlex Laboratories, Inc.
Allan M. Ross, MD
Research Grants and Speaker’s Honoraria: Boehringer
Ingelheim, Genentech, Roche.
Richard O. Russell, Jr., MD
This associate editor has nothing to disclose.
Thomas J. Ryan, MD
This associate editor has nothing to disclose.
Robert S. Schwartz, MD
Research Grants: Guidant Corporation, Boston Scientific, Medtronic/AVE.
Richard J. Shemin, MD
Consultant: St. Jude Medical, 3F Therapeutics, Inc., Edwards
Life Sciences.
Michael H. Sketch, Jr., MD
This associate editor has nothing to disclose.
Peter Sleight, MD
Research Grants and Speaker's Bureau: AstraZeneca, MSD, HMR
Aventis, King Pharmaceuticals, Monarch, Boehringer Ingelheim;
Speaker's Bureau: Knoll Pharmaceuticals, Servier, Sanofi.
Sidney C. Smith, Jr., MD
This associate editor's disclosures were not received at the time of production of the May 2005 issue.
Jane Somerville, MD
This associate editor has nothing to disclose.
William H. Spencer, III, MD
Stockholder: Medtronic, Inc., Pfizer Inc, Merck & Co.,
Inc., AstraZeneca, Boston Scientific, Genentech.
A. Jamil Tajik, MD
This associate editor's disclosures were not received at the time of production of the May 2005 issue.
Peter L. Thompson, MD
Consultant: AstraZeneca, Pfizer Inc.; Research Grant: Merck
& Co., Inc.
Daniel J. Ullyot, MD
Stockholder: Baxter International, Inc., Bristol-Myers Squibb,
Johnson & Johnson, Kimberly-Clark Corp., Medtronic, Inc.,
Pfizer Inc, Wyeth-Ayerst Laboratories.
Freek W.A. Verheugt, MD
This associate editor has nothing to disclose.
Robert A. Vogel, MD
Research Grants and Speaker’s Bureau: Pfizer Inc., Novartis,
Schering-Plough Corporation, Merck & Co., Inc.
Albert L. Waldo, MD
Consultant: BioSense Webster, Inc., Reliant Pharmaceuticals,
GlaxoSmithKline, ev3, Sanofi, Boehringer Ingelheim, CryoCor,
Inc.; Royalties: Mosby; Speaker’s Bureau: Reliant Pharmaceuticals,
Sanofi, Boehringer Ingelheim.
W. Douglas Weaver, MD
This associate editor has nothing to disclose.
Nanette Kass Wenger, MD
Research Grants/Contracts: Eli Lilly and Company, AstraZeneca
LP; Advisory Board/Committee: Eli Lilly and Company (Raloxifene),
Aventis Pharmaceuticals (Cardiology), Merck & Co., Inc.(Cardiology/Lipidology
Advisory Board), CV Therapeutics, Inc. (Ranolazine Advisory
Board), NitroMed (Heart Failure); Consultant: MED-ED (Heart
Disease in Women), Eli Lilly and Company , Pfizer Inc., Aventis
Pharmaceuticals, Bristol-Myers Squibb, Merck & Co., Inc.,
Women First Healthcare, Inc., CV Therapeutics, Inc.; Speakers
Bureau: Aventis Pharmaceuticals, Pfizer Inc., Merck &
Co., Inc., Bristol-Myers Squibb, Eli Lilly and Company; Data
Safety Monitoring Board: Pfizer Inc.
David O. Williams, MD
Consultant: Cordis Corporation, Guidant Corporation.
Eric S. Williams, MD
This associate editor has nothing to disclose.
William L. Winters, Jr., MD
This associate editor has nothing to disclose.
Michael J. Wolk, MD
This associate editor has nothing to disclose.
Douglas P. Zipes, MD
Research Grants: Medtronic, Inc.; Consultant: Procter &
Gamble, Medtronic, Inc., Janssen, DuPont Pharmaceuticals,
Cambridge Heart, Cyberonics, Abernathy Group, Genzyme.
About CME Credit for ACCEL
The American College of Cardiology
Foundation (ACCF) is accredited by the Accreditation Council
for Continuing Medical Education (ACCME) to provide continuing
medical education for physicians. The American College of
Cardiology Foundation takes responsibility for the content,
quality, and scientific integrity of this CME activity.
The
ACCF designates this educational activity for a maximum of
31 Category 1 AMA PRA Category 1 CreditsTM.
Physicians should only claim credit commensurate with the
extent of their participation in the activity.
About ACCEL
This educational activity consists of audio interviews, accessible
via CD/audiocassette, and online self-assessment questions.
While offering the CME credits noted above, ACCEL is not intended
to provide extensive training or certification in the field.
Target Audience
ACCEL is intended for all health care professionals who practice/study
cardiovascular medicine.
Learning Objective
Upon completion of this activity,
participants should be familiar with many of the recent advances
in cardiovascular medicine.
Disclaimer
The questions and answers found on www.services.acc.org/accel/cme/index.asp
are designed to stimulate thinking and motivate readers to
further research. Answers are based on the best judgment of
the author at the time the question was written. New knowledge,
insights, and perspectives may cause the reader to disagree
with an author’s answer. The American College of Cardiology
Foundation encourages thoughtful discussion and consideration
of each question’s answer.
Notice About Off-Label Use
ACCEL may include discussion of drugs or devices, or uses
of drugs or devices, that have not been approved by the Food
and Drug Administration (FDA) or have been approved by the
FDA for specific uses only. The FDA has stated that it is
the responsibility of the physician to determine the FDA clearance
status of each drug or device he or she wishes to use in clinical
practice.
ACCF is committed to the free exchange
of medical education. Inclusion of any discussion in this
program, including discussion of off-label uses, does not
imply an endorsement by ACCF of the uses, products, or techniques
presented.
Copyright
ACCEL is copyrighted by the American College of Cardiology
Foundation through the Library of Congress and thereby reserves
all rights of duplication and distribution of the information
contained in ACCEL. Use of the ACCEL tapes or CDs for purposes
other than individual or small group study is prohibited.
The College does not hold itself responsible for statements
made by any contributor. Statements or opinions expressed
in ACCEL reflect the views of the author and do not represent
official policy of the American College of Cardiology Foundation,
unless otherwise stated. |
